^
    Back
    Association details:
    Biomarker:CCND1 expression
    Cancer:Non Small Cell Lung Cancer
    Drug:erlotinib (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Study of Tarceva and Targretin in Stage I-II Lung Cancer

    Excerpt:
    ...Number of Participants With Change in Expression Level of Cyclin D1`Number of Participants With Change in Expression Level of Phosphorylated EGFR (pEGFR)...
    Trial ID:
    NCT00125372
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Biochem Pharmacol
    Title:

    Transcriptional activation of cyclin D1 via HER2/HER3 contributes to EGFR-TKI resistance in lung cancer

    Published date:
    06/11/2020
    Excerpt:
    Analysis of cyclin D1 expression in patients with non-small cell lung carcinoma (NSCLC) showed that its expression is negatively associated with overall survival and disease-free survival.
    DOI:
    10.1016/j.bcp.2020.114095